Objective: Inflammation plays a pivotal role in the atherosclerotic process, and some chemokines seem to be crucial in the pathogenesis of vascular damage. High-serum homocysteine, recently recognized as an independent risk factor for vascular disease might increase cytokine and chemokine levels, thus amplifying endothelial damage; moreover, it might worse insulin resistance, thus further contributing to enhance cardiovascular risk. The effect of folic acid supplementation in improving in vivo endothelial function is still debated. In this study, we investigated the effect of folic acid supplementation on insulin sensitivity and peripheral markers of inflammation in overweight healthy subjects. Design: The study was performed as an unmasked randomized placebo-controlled trial of 12 weeks duration. Subjects: Sixty healthy volunteers with normal glucose tolerance and BMI between 25 and 29 kg/m 2 were enrolled. Measurements: Biochemical parameters and plasma concentrations of homocysteine and of some inflammatory molecules were measured at baseline and at the end of the study, together with an estimation of insulin sensitivity. Results: Subjects receiving folic acid supplementation showed a decrement of homocysteine and an amelioration of insulin sensitivity; this treatment was also associated with a significant drop in the circulating concentration of monocyte chemoattractant protein-1, interleukin-8 and C-reactive protein, in the absence of any significant variation of BMI or fat mass. Conclusions: In healthy overweight subjects a short-term folic acid supplementation reduces the circulating level of some inflammatory mediators independently of weight change, thus suggesting a potential therapeutic role for folic acid in the protection from atherogenesis and cardiovascular diseases.
Introduction
Whether hyperhomocysteinemia should be considered a marker for cardiovascular disease or a major, independent risk factor is still debated. 1, 2 The mechanisms proposed for the vascular damage induced by hyperhomocysteinemia are heterogeneous, including impaired nitric oxide (NO)-dependent vasodilation, endothelial injury, increased oxidative stress, and induction of a procoagulant state. 3 Raised circulating levels of chemokines such as macrophage chemoattractant protein-1 (MCP-1) and interleukin-8 are markers of low-grade inflammation, thrombosis, and vascular injury by virtue of their action to drive leukocytes into inflamed tissues and to modulate the function of several cell types (endothelial cells, smooth muscle cells, and fibroblasts) involved in the formation of the atherosclerotic plaque. In the prone Apo E À/À mouse, for example, development of atherosclerotic lesions can be prevented by the concomitant knockout of the MCP-1 gene. 4 In apparently healthy individuals, elevated plasma concentrations of IL-8, largely expressed in the adipose tissue, 5 are associated with an increased risk of future CAD. 6 Interleukin-6 (IL-6) is a proinflammatory cytokine whose release by adipose tissue is increased in obesity and causally linked to insulin resistance. For this reason, these chemokines have been recently proposed as 'nontraditional' risk factors of atherosclerosis. 7, 8 C-reactive protein (CRP), another inflammatory marker, predicts acute cardiovascular events in healthy subjects and in patients with ischemic heart disease. Moreover, it exerts a series of direct proatherogenic effects, such as reduction of NO and prostacyclin and increase of several cell adhesion molecules.
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Homocysteine (tHcy) can enhance the expression of such chemokines in human endothelial cells, 10 thereby promoting the recruitment of leukocytes into the vascular wall, and accelerating the atherosclerotic process. High tHcy concentrations have been described in several clinical conditions associated with insulin resistance, such as type 2 diabetes, obesity, and hypertension, and have been suggested to play a role in the high cardiovascular risk typical of these diseases; 11, 12 it has been also described in peculiar conditions of insulin resistance as the polycystic ovary syndrome 13 and gestational diabetes, 14 but other studies have failed to confirm this association. 15, 16 In obese subjects, weight loss or physical training improves insulin resistance and the cardiovascular risk factor profile, yet has only minimal effects on plasma tHcy levels. 17, 18 In those studies [19] [20] [21] that have reported a reduction in inflammatory markers following weight loss, it is not clear whether and to what extent the changes in plasma tHcy levels might have contributed to this effect. Therefore, we designed the present study in order to test whether a short-term dietary supplementation with folate affects plasma insulin levels and some inflammatory markers in nondiabetic nonobese subjects.
Subjects and methods

Subjects
Sixty healthy volunteers aged 29-61 years were enrolled in the study ( . Subjects on any chronic drug treatment were excluded. At baseline, data on lifestyle and medication were collected by a standard questionnaire, and all subjects underwent a complete clinical examination. Blood pressure was measured in the sitting position with a mercury sphygmomanometer after a 10-min rest; the mean of the last two measurements was used for statistical analysis. Height, and weight were recorded, and body composition was determined by bioelectrical impedance using a BIA TBF300 instrument (Tanita Corp., Tokyo, Japan). Fasting blood samples were drawn to measure fasting plasma glucose, lipid profile, blood urea nitrogen (BUN) and serum creatinine, vitamin B 12 and folate concentrations, total plasma homocysteine, and levels of inflammatory markers. All subjects were then put on a modestly hypocaloric diet (1400 kcal/day, 55% carbohydrate, 25% protein, and 20% fat), and were randomly assigned to receive either placebo or folic acid treatment (2.5 mg /daily) for 3 months. They were also adviced to avoid the assumption of dietary supplements and of any anti-inflammatory drugs for the entire study period. At the end of this period, the baseline study protocol was repeated; patient's compliance was assessed by counting returned pills.
Laboratory methods
Plasma glucose and serum lipids were assayed by standard enzymatic methods. Plasma insulin was measured using radioimmunoassay (Linco Res, St Charles, MO, USA). Serum vitamins were determined by a chemiluminescent immunoassay (Diagnostic Products Corp., Los Angeles, CA, USA); intra-and inter-assay variation coefficients were 4.0 and 6.5% for vitamin B 12 , and 4.1 and 5.3% for folate, respectively. tHcy levels were measured on fasting plasma 
Results
All subjects completed the 3-month study with an adequate compliance. At baseline, the two groups of patients were well-matched for all clinical characteristics (Table 1) ; no subject presented clinical deficits in serum vitamin concentrations. Posttreatment, neither BMI nor fat mass changed significantly; similarly, none of the clinical or metabolic parameters was altered by intervention, with the exception of serum folate levels, which increased, and serum tHcy, which tended to decrease, in the vitamin-treated group. In contrast, fasting plasma insulin concentrations decreased significantly following folic treatment (placebo-adjusted difference ¼ À873 pmol/l, P ¼ 0.004). Likewise, the HOMA index was significantly reduced in the folate group. Treatment with folic acid was associated with a significant drop in the circulating levels of CRP (placebo-adjusted difference ¼ À0.0770.03 mg/l, P ¼ 0.03), IL-8 (placebo-adjusted difference ¼ À471 pg/ml, Po0.0001), and MCP-1 (placebo-adjusted difference ¼ À57710 pg/ml, Po0.0001), whereas no significant change occurred in plasma IL-6 levels ( Table 2 ).
In the whole data set, treatment-induced changes in CRP, IL-8, or MCP-1 levels were reciprocally related to the corresponding changes in plasma folate concentration. For IL-8 and MCP-1, the inverse relationships were still statistically significant (partial r's of À0.54, À0.42, respectively, both Po0.001) after adjusting for the changes in HOMA-IR. Treatment-induced changes in plasma insulin concentration were reciprocally related to the corresponding changes in IL-8 and MCP-1 levels (Table 3) . When restricting the analysis to the active treatment group, changes in MCP-1 levels were directly related to changes in HOMA (Figure 1 ).
Discussion
Adipose tissue is metabolically active and secretes various chemokines and proinflammatory cytokines, such as IL-6, TNFa and MCP-1. 23, 24 It is, however, unclear to what extent adipose tissue contributes to the elevated circulating levels of these factors in obesity and what other tissues participate in the inflammatory process. Weight loss and physical training have both been shown to decrease the amount of visceral fat and also lower plasma levels of these inflammatory mediators, 25 as well as a caloric restriction that, even in the absence of weight loss, might determine a redistribution of the parameters of body composition, thus contributing to an improvement of the inflammatory state. 
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In cultured human endothelial cells, homocysteine has been shown to induce the expression of the proinflammatory chemokines, MCP-1 and IL-8. 10, 26 Whether intentional changes in tHcy concentrations can modulate the inflammatory response in vivo is still under scrutiny. In the only study so far in the literature, 1 month of supplementation with folic acid (5 mg/day) plus vitamin B12 (0.5 mg/day) significantly reduced plasma insulin concentrations in subjects with the metabolic syndrome (defined according to the National Cholesterol Education Program-Adult Treatment Panel-III criteria). 27 However, the impact of this treatment on inflammatory markers was not determined.
In the current study, we recruited healthy, overweight subjects to rule out the possibility that associated dyslipidemia, hypertension or marked visceral obesity may have a permissive role on the inflammatory response even in the normohomocysteinemic range. Furthermore, our volunteers were not, and had never been, on any medication, thereby excluding any pharmacological interference. Finally, BMI and fat mass were similar between the treatment groups both basally and at the end of the trial, thus minimizing the possibility that changes in cytokine levels might be written off to changes in fat mass, and this was exactly the aim of putting all the subject under the same dietetic regimen during the study period.
The main results of our short-term intervention, together with an expected reduction in tHcy in subjects assuming folic acid, were a significant reduction in plasma insulin concentrations and HOMA estimates of insulin resistance accompanied by, and quantitatively related to, decrements in the circulating levels of three cytokines (CRP, IL-8, and MCP-1). The inflammatory markers we measured are involved in different phases of the inflammatory process: IL-6 drives the acute inflammatory response and orchestrates the production of acute phase proteins such as CRP. MCP-1 is a specific proinflammatory cytokine generated by endothelial cells and monocytes, whose function is to attract leukocytes to the inflammatory site. IL-8 has been reported to trigger the firm adhesion of monocytes to vascular endothelium under low-flow conditions. 28, 29 The homocysteine-lowering effects of folic acid and vitamin B12 have been well documented. 30 At baseline, our subjects had circulating Hcy levels that were well within the normal range (5-15 mmol/l). The folic acid supplementation regimen we adopted was relatively short-term (3 months) and relatively low-dose (2.5 mg/day); yet, it was able to induce a significant reduction of tHcy levels. Although we cannot rule out an effect of consumption of folate-enriched foods, these are neither popular nor easily available in our country. Interestingly, the most prominent treatment-induced changes we observed concerned IL-8 and MCP-1 (À20% for both), that is, proteins mainly active on monocyte recruitment and regulated in a similar fashion. 31 The effect of vitamin supplementation on markers of the acute phase was less evident, with a small, if significant, drop in CRP levels but no detectable decrement in IL-6 levels. These differences could be interpreted to reflect the fact that homocysteine plays a greater role in endothelial damage 27 and atherogenesis than in the inflammatory response. Alternatively, changes in IL-6 levels may be more directly dependent on loss of fat mass (particularly visceral fat), which, in our study subjects, was negligible. However, further studies on larger cohorts would be needed to consolidate this interpretation. Several studies have provided support for the hypothesis that insulin resistance may be associated with chronic subclinical inflammation, 32, 33 and both CRP and IL-6 are increased in insulin-resistant subjects. 34 Similarly, insulin sensitivity has been found to correlate with plasma tHcy levels in lean and obese individuals. 35 Acute hyperinsulinemia raises circulating IL-8 levels, and Bruun et al. 36 have observed a decrease in IL-8 expression in adipose tissue after incubation with insulin-sensitizing agents (thiazolidinediones and metformin). In our study, we observed a folateinduced drop in circulating insulin levels and the HOMA index of insulin resistance in the absence of even a trend for weight loss, suggesting an independent effect of folic acid supplementation on insulin action. In addition to homocysteine, one can postulate a direct influence of folic acid on nitric oxide function, given that 5-methyltetrahydrofolate, the main circulating metabolite of folate, can increase NO production and directly scavenge superoxide radicals. Moreover, 5-methyltetrahydrofolate stimulates endogenous H(4)B regeneration, a cofactor necessary for eNOS synthesis, and increases arginine transport into the cells. 37 Previous studies looking at such an association between insulin sensitivity and folate treatment have yielded mixed results, as some have been positive 38 and some neutral 15, 39 in small groups of nondiabetic subjects. Data on the folate and vitamin status of participants in all these studies are not available. Since folate intake is the most important determinant of plasma tHcy, it is possible that lack of correction for nutritional factors may have been responsible for these variable results. Incidentally, in our subjects, baseline levels of either homocysteine or folate were not significantly different between the folate and placebo group, suggesting that measurements of baseline homocysteine or folate concentrations are of limited value in predicting folate response. Furthermore, in no previous study have the folate-induced changes in insulin (Table 3) or HOMA ( Figure 1 ) been found to be quantitatively related to reductions in IL-8 and MCP-1, as we observed in our cohort. Whether this prospective association implies a cause-effect relationship, with the improvement in insulin action being responsible for the anti-inflammatory effect, remains to be decided.
In conclusion, in healthy overweight subjects a short-term course of folate supplementation reduces the circulating level of some inflammatory mediators independently of weight change. As MCP-1 and IL-8 are major chemokines for leukocyte trafficking, largely represented in atheromatous plaques and capable of enhancing the instability of the plaque (through downregulation of tissue inhibitor of metalloproteinase expression, 40 the current findings suggest 
